Steatotic Liver Disease has Surpassed Viral Hepatitis as the Leading Cause of Cirrhosis in the US Veterans Health System.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 41705703.
- Also identified by DOI 10.14309/ajg.0000000000003966.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Contemporary population-level estimates of the burden of cirrhosis using the revised steatotic liver disease (SLD) nomenclature are lacking. Retrospective cohort study of patients with incident cirrhosis from 2008 to 2023 within the Veterans Health Administration. Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the leading contributor to cirrhosis incidence and prevalence. Although hepatitis C virus cirrhosis has declined, it remains highly prevalent. Incident MASLD cases are balanced by deaths, whereas incident metabolic and alcohol-associated liver disease and alcohol-associated liver disease cases exceeded deaths. Substantial epidemiologic shifts in cirrhosis in the United States over the past decade, driven by the rising burden of SLD, underscore the need for multidisciplinary strategies targeting metabolic risk factors and alcohol use.